EU MDR / IVDR

Comprehensive guide to the EU's new Breakthrough Device (BtX) framework under MDCG 2025-9 and the EMA pilot program launching Q2 2026. Covers eligibility criteria, application process, benefits for manufacturers, comparison with the FDA Breakthrough Device Program, and what this means for IVD companies.

Detailed analysis of MedTech Europe's May 2026 position paper on the proposed MDR/IVDR revision. Covers breakthrough/orphan pathways, cybersecurity, AI integration, IVDR-specific concerns, and what manufacturers need to know about the coming legislative process.

On May 7, 2026, the EU Council and Parliament reached a provisional deal to simplify AI Act rules. This guide breaks down what changed, what the product safety exemption means for medical devices, the new compliance timelines for AI-enabled SaMD and IVDs, and what manufacturers must do now.

A complete guide to Commission Implementing Regulation (EU) 2026/977, published May 4, 2026, which sets uniform quality management and procedural requirements for Notified Bodies conducting conformity assessments under the MDR and IVDR. Covers maximum timelines, clock-stop rules, quotation transparency, re-certification procedures, and what manufacturers need to know.

A practical survival guide for IVD manufacturers facing the May 26, 2026 IVDR Class C transition deadline. Covers who must apply to a Notified Body, the September 2026 agreement deadline, conditions for extended market access through 2028, common pitfalls, and a step-by-step action plan.

A practical guide to the April 2026 MDCG updates affecting every EU medical device and IVD manufacturer. Covers MDCG 2021-24 Rev.1 classification guidance changes, EMDN v3/2026 code updates (MDCG 2026-1, 2026-2, 2026-3, MDCG 2021-12 Rev.2), the Borderline and Classification Manual Version 5, and what manufacturers must do to stay compliant.

A field-by-field evidence matrix mapping MDR Annex II/III technical documentation, ISO 14971 risk management, PMS/PMCF, cybersecurity, data governance, human oversight, and QMS records to EU AI Act high-risk obligations — for manufacturers who must comply with both frameworks simultaneously.

A systematic playbook for diagnosing and resolving EUDAMED bulk upload validation errors — covering XSD schema failures, Basic UDI-DI/UDI-DI mismatches, EMDN code issues, certificate linkage errors, DTX error codes, NB confirmation bottlenecks, and a pre-upload validation checklist.

Step-by-step guide to building a dual PMSR/PSUR reporting architecture that satisfies both EU MDR/IVDR and Great Britain SI 2024/1368 requirements — data-period alignment, GB-specific content, MHRA standardized format, FSCA linkage, trend reporting, record retention, and responsible-owner mapping.

How to prepare the consultation file for IVDR companion diagnostics — notified body submission to EMA or national medicinal product authorities, package contents, analytical and clinical performance evidence, drug label alignment, timing, deficiency risks, and the Team-NB V2 decision flowchart for significant changes.

A practical guide to implementing MDR Article 88 trend reporting — covering denominator selection, expected frequency calculation, statistical significance testing, severity escalation, complaint coding, CAPA linkage, PSUR/PMSR integration, and the MDCG 2025 draft Q&A requirements.

How to design a PMCF survey under EU MDR that Notified Bodies accept as Level 4 clinical evidence — sample frame construction, inclusion/exclusion criteria, endpoint mapping to CER claims, acceptance criteria, statistical power, bias controls, adverse event capture, and when surveys alone are insufficient.

Practical playbook for responding to Notified Body deficiencies on SSCP documents under EU MDR — response table format, clinical benefit wording fixes, residual risk language, patient readability, CER/IFU alignment, translation consistency, and EUDAMED publication readiness.

2026 is the most consequential year for medical device UDI compliance globally. Mandatory deadlines hit in the EU (May 28), Switzerland (July 1), Australia (July 1), and China. This guide covers every active UDI system, class-by-class deadlines, data requirements, and what happens if you miss them.

Switzerland's swissdamed database becomes mandatory on July 1, 2026, requiring all medical device manufacturers to register products and upload UDI data. This guide covers the Product Module, CH REP requirements, M2M functionality, grace period rules, immediate registration triggers, and the consequences of non-compliance.

Complete guide to the GLP-1 drug-delivery device landscape in 2026 — auto-injector pens, oral delivery devices, combination product regulatory pathways, FDA and EU MDR requirements, and market outlook.

An analysis of the EU MDR and IVDR Notified Body capacity crisis using 2026 survey data — 33,175 MDR applications vs 17,549 certificates issued, 13–18 month review times, IVDR Class C deadline, and a practical action plan for manufacturers facing certification gaps.

How the EU Corporate Sustainability Reporting Directive affects medical device manufacturers — scope, ESRS standards, double materiality, timelines, Omnibus simplification, and practical compliance steps for MedTech.

How to select, evaluate, and change Notified Bodies under EU MDR and IVDR — capacity constraints, selection criteria, transfer process, 2026 implementing regulation, and timeline planning.

How Good Clinical Practice applies to medical device clinical trials — navigating ISO 14155:2026 and ICH E6(R3), sponsor and investigator responsibilities, informed consent, safety reporting, and audit readiness.